Posted by Michael Wonder on 07 Sep 2017
Verastem expands duvelisib development program to include peripheral T-cell lymphoma
6 Septemner 2017 - Duvelisib receives fast track designation from FDA in peripheral T-cell lymphoma; company to initiate a phase 2 clinical trial by year end 2017.
Duvelisib has been granted fast track designation by the U.S. FDA for the treatment of patients with peripheral T-cell lymphoma who have received at least one prior therapy.
Duvelisib, Verastem’s lead drug candidate, is an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma being investigated for the treatment of hematologic cancers, including chronic lymphocytic leukaemia /small lymphocytic lymphoma, indolent non-Hodgkin lymphoma and other T-cell lymphomas.
